Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.

MLA

Holdhoff, Matthias, et al. “Phase I Dose-Escalation Study of Procaspase-Activating Compound-1 in Combination with Temozolomide in Patients with Recurrent High-Grade Astrocytomas.” Neuro-Oncology Advances, vol. 5, no. 1, July 2023, p. vdad087. EBSCOhost, https://doi.org/10.1093/noajnl/vdad087.

APA

Holdhoff, M., Nicholas, M. K., Peterson, R. A., Maraka, S., Liu, L. C., Fischer, J. H., Wefel, J. S., Fan, T. M., Vannorsdall, T., Russell, M., Iacoboni, M., Tarasow, T. M., Hergenrother, P. J., Dudek, A. Z., & Danciu, O. C. (2023). Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas. Neuro-Oncology Advances, 5(1), vdad087. https://doi.org/10.1093/noajnl/vdad087

Chicago

Holdhoff, Matthias, M Kelly Nicholas, Richard A Peterson, Stefania Maraka, Li C Liu, James H Fischer, Jeffrey S Wefel, et al. 2023. “Phase I Dose-Escalation Study of Procaspase-Activating Compound-1 in Combination with Temozolomide in Patients with Recurrent High-Grade Astrocytomas.” Neuro-Oncology Advances 5 (1): vdad087. doi:10.1093/noajnl/vdad087.